A Discrepancy between (131)I-Metaiodobenzylguanidine ((131)I-MIBG) Scintigraphy and (18)F-FDG PET/CT after (131)I-MIBG Therapy in a Patient with Recurred Malignant Pheochromocytoma.
- Author:
Kun Ho KIM
1
;
Seong Min KIM
;
Young Duk SEO
Author Information
1. Department of Nuclear Medicine, Chungnam National University Hospital, Daejeon, Korea. sminee@cnuh.co.kr
- Publication Type:Case Report
- Keywords:
Malignant pheochromocytoma;
(131)I-metaiodobenzylguanidine ((131)I-MIBG);
(18)F-FDG PET/CT
- MeSH:
Adrenalectomy;
Electrons;
Female;
Humans;
Liver;
Lung;
Lymph Nodes;
Middle Aged;
Neoplasm Metastasis;
Pheochromocytoma;
Thorax
- From:Nuclear Medicine and Molecular Imaging
2009;43(6):582-587
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A 59-year-old woman who was diagnosed with malignant pheochromocytoma underwent (18)F-fluorodeoxyglucose positron emission tomography/computed tomography ((18)F-FDG PET/CT). She had undergone left adrenalectomy for pheochromocytoma 4 years previously. Recent multiple metastatic pulmonary nodules were noted on the chest X-ray. After treatment with (131)I-metaiodobenzylguanidine ((131)I-MIBG) with 7.4 GBq, post-therapy (131)I-MIBG scintigraphy depicted multiple distant metastases including lung, liver, abdominal para-aortic and mesenteric lymph nodes. (18)F-FDG PET/CT also depicted multiple metastases in lung, liver, and abdominal para-aortic lymph nodes, but some lesions were not shown. In this case, (131)I-MIBG scintigraphy found additional lesions in metastatic malignant pheochromocytoma.
